Galderma Group N
GALD.SW
| Exchange: | SW |
| Currency | Swiss Franc |
| Open Figi: | BBG01LYFLBM9 |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Description: | Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland. |
| Address: | Zählerweg 10, Zug, Switzerland, 6300 |
| Website: | https://www.galderma.com |
| Full Time Employees: | 6545 |
| Updated On: | 2024-08-02 |
Highlights
| Market Capitalization: | 17825697792 |
| Market Capitalization Mln: | 17825.69 |
| Wall Street Target Price: | 77.32 |
| EPS Estimate Current Year: | 1.78 |
| EPS Estimate Next Year: | 2.59 |
Technicals
| 52 Week High: | 84.92 |
| 52 Week Low: | 53 |
| 50 Day MA: | 70.60 |
| 200 Day MA: | 69.00 |
Earnings
| Report Date: | 2024-10-24 |
| Date: | 2024-09-30 |
| Before After Market: | Before Market |
| Report Date: | 2024-07-25 |
| Date: | 2024-06-30 |
| Before After Market: | Before Market |
| Eps Actual: | 0.55 |
| Eps Estimate: | 1.12 |
| Eps Difference: | -0.57 |
| Surprise Percent: | -50.89 |
| Date: | 2025-12-31 |
| Period: | +1y |
| Growth: | 0.45 |
| Earnings Estimate Avg: | 2.59 |
| Earnings Estimate Low: | 2.40 |
| Earnings Estimate High: | 2.85 |
| Earnings Estimate Year Ago Eps: | 1.78 |
| Earnings Estimate Number Of Analysts: | 7.00 |
| Earnings Estimate Growth: | 0.45 |
| Revenue Estimate Avg: | 4442700000.00 |
| Revenue Estimate Low: | 4355070000.00 |
| Revenue Estimate High: | 4513940000.00 |
| Revenue Estimate Number Of Analysts: | 7.00 |
| Revenue Estimate Growth: | 0.12 |
| Eps Trend Current: | 2.59 |
| Eps Trend7days Ago: | 2.57 |
| Eps Trend30days Ago: | 2.64 |
| Eps Revisions Up Last7days: | 1.00 |
| Eps Revisions Up Last30days: | 2.00 |
| Date: | 2024-12-31 |
| Earnings Estimate Avg: | 1.78 |
| Earnings Estimate Low: | 1.22 |
| Earnings Estimate High: | 1.92 |
| Earnings Estimate Number Of Analysts: | 7.00 |
| Revenue Estimate Avg: | 3967880000.00 |
| Revenue Estimate Low: | 3941700000.00 |
| Revenue Estimate High: | 4009230000.00 |
| Revenue Estimate Number Of Analysts: | 7.00 |
| Eps Trend Current: | 1.78 |
| Eps Trend7days Ago: | 1.78 |
| Eps Trend30days Ago: | 1.82 |
| Eps Revisions Up Last30days: | 1.00 |
| Date: | 2024-09-30 |
| Period: | +1q |
| Date: | 2024-06-30 |
| Earnings Estimate Avg: | 1.00 |
| Earnings Estimate Low: | 1.00 |
| Earnings Estimate High: | 1.00 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Eps Trend Current: | 1.00 |
| Eps Trend7days Ago: | 1.00 |
| Eps Trend30days Ago: | 1.02 |
| Date: | 2024-09-30 |
| Eps Actual: | 0.5 |